Is TCRT undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of TCRT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate TCRT's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate TCRT's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for TCRT?
Key metric: As TCRT barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.
The above table shows the Price to Book ratio for TCRT. This is calculated by dividing TCRT's market cap by their current
book value.
What is TCRT's PB Ratio?
PB Ratio
1.4x
Book
US$2.72m
Market Cap
US$3.83m
TCRT key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Price-To-Book vs Industry: TCRT is good value based on its Price-To-Book Ratio (1.4x) compared to the US Biotechs industry average (1.9x).
Price to Book Ratio vs Fair Ratio
What is TCRT's PB Ratio
compared to its
Fair PB Ratio?
This is the expected PB Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
TCRT PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio
1.4x
Fair PB Ratio
n/a
Price-To-Book vs Fair Ratio: Insufficient data to calculate TCRT's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.